Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, METiS TechBio enters a strategic collaboration with Eli Lilly worth up to roughly $1.1 billion to develop next-generation, tissue-specific LNP delivery technologies, Incubate’s John Stanford argues that Most-Favored Nation deals are dampening large pharma’s appetite for biotech acquisitions, and the FDA grants accelerated approval to GSK’s Jemperli as the first and only immunotherapy for MSI-H/dMMR locally advanced rectal cancer.

METiS TechBio announces a strategic collaboration with Eli Lilly and Company to research and develop next-generation lipid nanoparticle delivery technologies for tissue-specific drug delivery. METiS stands to receive a low double-digit-million upfront payment, up to approximately $1.1 billion in milestone payments, and tiered royalties, contributing its AI-driven lipid discovery platform, AiLNP, while Lilly brings its development and commercialization expertise. Terms including the specific disease areas targeted remain undisclosed.

Incubate executive director John Stanford contends that Most-Favored Nation pricing deals are creating a disincentive across the pharma value chain that could curb large companies’ appetite for acquiring small biotechs. He notes that roughly two-thirds of new drugs originate from small biotechs later acquired by larger manufacturers, and warns that continued pressure on risk-taking could cede ground in pharmaceutical innovation to China.

Finally, the FDA grants accelerated approval to GSK’s Jemperli (dostarlimab-gxly), making it the first and only immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer. The approval rests on the single-arm Phase II Azur-1 trial of 154 patients, in which investigator-assessed data showed a 68% 12-month response rate, with independent-review data still maturing at 47%. Continued approval may depend on confirmatory trials.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.